79 / 1542
Sonke, Belderbos. Sem Radiat Oncol 2011; Brink,
et al
., Radiother Oncol 2014; Zwienen,
et al
. Int J Radiat Oncol Biol Phys
2008; Berkovic,
et al
. Acta Oncol 2015
Overall goal: lower NTCP and higher TCP due to dose escalation
I
Tumor regression 0.6%-2.4% per day, fast decrease in tumor volume is
associated with worse outcome (non-adenocarcinoma patients)
I
Measurable tumor regression occurs in 40% of the patients (progression
only in 1%), and is mostly visible in the fourth week of
radio(chemo)therapy
I
Tumor volume decrease is larger in patients simultaneously treated with
radiochemotherapy than in those treated sequentially (50.1%
versus
33.7%,
p
=0.003)
I
Planning studies on possible dose escalation have reported different
results
Target volume adaptation in NSCLC